Ecalta is used to treat patients from one month of age with invasive candidiasis (a fungal infection caused by a yeast called Candida). ‘Invasive’ means that the fungus has spread into the bloodstream.
Ecalta contains the active substance anidulafungin.
Ecalta : EPAR - Medicine overview (PDF/117.96 KB)
First published: 05/11/2009
Last updated: 31/07/2020
Ecalta : EPAR - Risk-management-plan summary (PDF/113.2 KB)
First published: 31/07/2020
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Pfizer Europe MA EEIG
|Date of issue of marketing authorisation valid throughout the European Union||
Boulevard de la Plaine 17
03/06/2020 Ecalta - EMEA/H/C/000788 - II/0040
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Antimycotics for systemic use
Treatment of invasive candidiasis in adults and paediatric patients aged 1 month to < 18 years.